AR054258A1 - PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE A COMBINATION OF A SELECTIVE MODULATOR OF STROGEN RECEPTORS AND AN AROMATASE INHIBITOR - Google Patents

PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE A COMBINATION OF A SELECTIVE MODULATOR OF STROGEN RECEPTORS AND AN AROMATASE INHIBITOR

Info

Publication number
AR054258A1
AR054258A1 AR20060101616A ARP060101616A AR054258A1 AR 054258 A1 AR054258 A1 AR 054258A1 AR 20060101616 A AR20060101616 A AR 20060101616A AR P060101616 A ARP060101616 A AR P060101616A AR 054258 A1 AR054258 A1 AR 054258A1
Authority
AR
Argentina
Prior art keywords
phenyl
acceptable salt
aromatase inhibitor
prodrug
patient
Prior art date
Application number
AR20060101616A
Other languages
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR054258A1 publication Critical patent/AR054258A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmacéuticas y métodos de tratamiento que comprenden administrar a un paciente que lo necesite una combinacion de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-il-etoxi)-fenil]-5,6,7,8-tetrahidronaftalen-2-ol o una sal o profármaco farmacéuticamente aceptable del mismo, y un inhibidor de aromatasa. En particular, la presente se refiere a composiciones farmacéuticas y a métodos de tratamiento que comprenden administrar a un paciente que lo necesite una combinacion de (-)-cis-6- fenil-5-[4-(2-pirrolidin-1-il-etoxi)-fenil]-5,6,7,8-tetrahidronaftalen-2-ol o una sal o profármaco aceptable del mismo, y un inhibidor de aromatasa seleccionado de aminoglutetimida, formestano, atamestano, anastrazol, fadrozol, finrozol, letrozol, vorozol, 4-[N-(4-bromobencil)-N-(4-cianofenil)amino]-4H-1,2,4-triazol o exemestano, o una sal farmacéuticamente aceptable del mismo. Reivindicacion 6: Un método para tratar la osteoporosis senil, osteoporosis posmenopáusica, fracturas oseas, injertos de hueso, cáncer de mama, cáncer de ovario, obesidad, osteopenia, osteoporosis masculina, fragilidad, lesiones musculares o sarcopenia en un paciente, dicho método comprende administrar a un paciente que lo necesite, una cantidad terapéuticamente eficaz de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-il-etoxi)-fenil]-5,6,7,8-tetrahidronaftalen-2-ol o una sal o profármaco farmacéuticamente aceptable del mismo y una cantidad terapéuticamente eficaz de un inhibidor de aromatasa o de una sal o profármaco farmacéuticamente aceptable el mismo.Pharmaceutical compositions and treatment methods comprising administering to a patient in need of a combination of (-) - cis-6-phenyl-5- [4- (2-pyrrolidin-1-yl-ethoxy) -phenyl] -5, 6,7,8-tetrahydronaphthalen-2-ol or a pharmaceutically acceptable salt or prodrug thereof, and an aromatase inhibitor. In particular, this refers to pharmaceutical compositions and treatment methods comprising administering to a patient in need thereof a combination of (-) - cis-6- phenyl-5- [4- (2-pyrrolidin-1-yl- ethoxy) -phenyl] -5,6,7,8-tetrahydronaphthalen-2-ol or an acceptable salt or prodrug thereof, and an aromatase inhibitor selected from aminoglutethimide, formestane, atamestane, anastrazole, fadrozole, finrozole, letrozole, vorozole , 4- [N- (4-Bromobenzyl) -N- (4-cyanophenyl) amino] -4H-1,2,4-triazole or exemestane, or a pharmaceutically acceptable salt thereof. Claim 6: A method of treating senile osteoporosis, postmenopausal osteoporosis, bone fractures, bone grafts, breast cancer, ovarian cancer, obesity, osteopenia, male osteoporosis, frailty, muscle injuries or sarcopenia in a patient, said method comprises administering to a patient in need, a therapeutically effective amount of (-) - cis-6-phenyl-5- [4- (2-pyrrolidin-1-yl-ethoxy) -phenyl] -5,6,7,8- tetrahydronaphthalen-2-ol or a pharmaceutically acceptable salt or prodrug thereof and a therapeutically effective amount of an aromatase inhibitor or a pharmaceutically acceptable salt or prodrug thereof.

AR20060101616A 2005-04-25 2006-04-24 PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE A COMBINATION OF A SELECTIVE MODULATOR OF STROGEN RECEPTORS AND AN AROMATASE INHIBITOR AR054258A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67480705P 2005-04-25 2005-04-25

Publications (1)

Publication Number Publication Date
AR054258A1 true AR054258A1 (en) 2007-06-13

Family

ID=36693972

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060101616A AR054258A1 (en) 2005-04-25 2006-04-24 PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE A COMBINATION OF A SELECTIVE MODULATOR OF STROGEN RECEPTORS AND AN AROMATASE INHIBITOR

Country Status (6)

Country Link
EP (1) EP1937251A2 (en)
JP (1) JP2006306872A (en)
AR (1) AR054258A1 (en)
CA (1) CA2605796A1 (en)
TW (1) TW200716094A (en)
WO (1) WO2006114702A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0711525A2 (en) 2006-06-02 2011-11-01 Pear Tree Women S Health Care Pharmaceutical composition and method for treating symptoms of atrophic vaginitis
EP2070943A1 (en) * 2007-12-14 2009-06-17 Crystal Pharma, S.A. Process for obtaining 6-Alkylidenandrost-1,4-diene-3one
WO2011002096A1 (en) * 2009-07-03 2011-01-06 独立行政法人理化学研究所 Labeling compound for pet
US9370505B2 (en) 2011-09-08 2016-06-21 Mereo Biopharma 2 Limited Pharmaceutical compositions comprising an aromatse inhibitors
WO2017189976A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US20040024044A1 (en) * 2000-09-08 2004-02-05 Di Salle Enrico Exemestane as chemopreventing agent
AR034142A1 (en) * 2000-09-08 2004-02-04 Sloan Kettering Inst Cancer A PHARMACEUTICAL COMPOSITION, METHOD FOR MANUFACTURING A MEDICINAL BASED ON SUCH COMPOSITION AND USE OF THE COMPOSITION
WO2003017974A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
CN1713915A (en) * 2001-10-10 2005-12-28 法马西亚意大利公司 Methods for preventing and treating bone loss with steroid compounds
CN1929835A (en) * 2004-01-13 2007-03-14 惠氏公司 Treatment of aromatase inhibitor therapy-related osteoporosis
JP2008518902A (en) * 2004-11-04 2008-06-05 ファイザー・プロダクツ・インク Combination therapy of CTLA4 antibody and aromatase inhibitor for breast cancer

Also Published As

Publication number Publication date
EP1937251A2 (en) 2008-07-02
CA2605796A1 (en) 2006-11-02
TW200716094A (en) 2007-05-01
JP2006306872A (en) 2006-11-09
WO2006114702A2 (en) 2006-11-02
WO2006114702A3 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
JP5480623B2 (en) Triazole compounds that modulate HSP90 activity
CY1109860T1 (en) FACTORS OF HISTAMIN H3 CONTAINERS, PREPARATION AND THERAPEUTIC USES
AU2006272652B2 (en) 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders
FR16C0021I2 (en) AZETIDINES AS MEK INHIBITORS AND THEIR USE FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AR054258A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE A COMBINATION OF A SELECTIVE MODULATOR OF STROGEN RECEPTORS AND AN AROMATASE INHIBITOR
CA2983927A1 (en) K-ras modulators
JP2015500887A5 (en)
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
CO5670328A2 (en) PHARMACEUTICAL COMPOSITIONS AND PROCEDURES THAT INCLUDE COMBINATIONS OF DERIVATIVES OF 2-ALQUILIDEN-19-NOR-VITAMIN D AND AN AGRONIST / ANTAGONIST OF STROGENS
JP2016516043A5 (en)
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
MXPA04002037A (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity.
MX2021006552A (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia.
WO2003105771A3 (en) 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
MX2023001468A (en) Treatment of prostate cancer.
RU2007102274A (en) PIPERASINDIONES AS AN OXYTOCINE RECEPTOR ANTAGONISTS
JP2010503674A (en) Angiogenic compounds
DE602006017728D1 (en) CANCER TREATMENT BY AGENT AND 2-DEOXYGLUCOSE
ATE403426T1 (en) OPIOID RECEPTOR ACTIVE 4-(3-HYDROXYPHENYL) OR 4-(3-ALKOXYPHENYL)-1,2,4-TRIAZOLE COMPOUNDS
BRPI0411324A (en) pharmaceutical compositions and methods of treating histamine-mediated response in patients
RU2004104329A (en) Acylsemicarbazides as inhibitors of a cyclin-dependent kinase useful as anti-cancer and anti-proliferative agents
RU2007147957A (en) The combination of pyrimidylamino-benzamide derivatives and imatinib for the treatment or prevention of proliferative diseases
EA201000656A1 (en) AMINO DERIVATIVES OF 1,2,4-TRIAOSOL AS MGLUR5 MODULATORS
DE60309887D1 (en) COMBINATION OF AN AROMATASE WITH A BISPHOSPHONATE
RU2006108557A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND PARATHYROID HORMONE AND METHODS (TREATMENTS)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal